Shuguang Zhu serves as the Senior Vice President of CMC & Tech Operations at Pliant Therapeutics, where he leverages his extensive experience in Chemistry, Manufacturing, and Controls (CMC) to drive the development of innovative therapies. With a proven track record in successfully advancing new chemical...
Shuguang Zhu serves as the Senior Vice President of CMC & Tech Operations at Pliant Therapeutics, where he leverages his extensive experience in Chemistry, Manufacturing, and Controls (CMC) to drive the development of innovative therapies. With a proven track record in successfully advancing new chemical entities (NCEs) like Austedo and Zurampic to market, Shuguang brings a wealth of expertise in drug development from early discovery through to commercial launch. His leadership encompasses the management of a multifaceted CMC department, which includes Drug Substance (DS), Drug Product (DP), Analytical Development/Quality Control (AD/QC), Quality Assurance (QA), and Clinical Supply Chain (CSC).
At Pliant Therapeutics, Shuguang is focused on building a high-performing CMC team capable of efficiently managing both internal and external resources. His strategic oversight ensures that small molecule and antibody drug development programs progress seamlessly from IND enabling studies through pivotal trials to commercial readiness. Shuguang’s rich knowledge of Good Manufacturing Practices (GMP) is complemented by his hands-on experience in API process development, formulation, and technology transfer, making him a vital asset in navigating the complexities of drug development.
His skills in problem management and SOP development are instrumental in establishing robust operational frameworks that enhance productivity and compliance. Additionally, his involvement in GMP kilo lab and chemical pilot plant build-out initiatives underscores his commitment to fostering an environment conducive to innovation and quality. As Pliant Therapeutics continues to advance its pipeline, Shuguang Zhu's leadership and expertise are pivotal in ensuring the successful delivery of transformative therapies to patients in need.
